MAPLE GROVE, Minn., March 11, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), a privately held, specialty pharmaceutical company committed to the development of new treatments for diseases of the central nervous system (CNS), is proud to sponsor emerging data for three investigational drug programs in epilepsy at the 65th Annual Meeting of the American Academy of Neurology (AAN) in San Diego, CA, March 16-23, 2013.
Upsher-Smith's CNS pipeline consists of two Phase III programs: USL255 (topiramate), an investigational extended-release topiramate for the management of epilepsy in adults; and USL261 (midazolam) for the intranasal rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity, often called seizure clusters. Additionally, USL260 (tonabersat) is a potential first-in-class neuronal gap junction modulator in Phase I of development for treatment of epilepsy.
"Upsher-Smith is committed to improving the lives of people living with epilepsy by developing innovative treatments to address the unmet needs of those who suffer from this condition," said William Pullman, MB BS, BMedSc, PhD, FRACP, Chief Scientific Officer, Upsher-Smith. "We are very pleased with the progress that has been made with each of our investigational CNS drug programs and are excited to share our ongoing scientific research in epilepsy at AAN's Annual Meeting."
Upsher-Smith sponsored posters include:
Single, High Doses of USL255, an Extended-Release Topiramate Formulation, Are Well Tolerated and Demonstrate a Dose-Proportional Pharmacokinetic Profile in Healthy Subjects Poster 04.212; Session P04: Epilepsy: Antiepileptic Medications: Special Populations and Pharmacokinetics; Wednesday, March 20, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m.
Safety and Pharmacodynamics of USL261, a Novel Formulation of Midazolam Optimized for Intranasal Administration P02.211; Session P02: Epilepsy: Novel Therapeutics and Basic Science; Tuesday, March 19, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m.
Pharmacokinetics of USL261, a Novel Formulation of Intranasal Midazolam Poster 02.212; Session P02: Epilepsy: Novel Therapeutics and Basic Science; Tuesday, March 19, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m.
Tonabersat, a Novel Investigational Anti-Seizure Drug, Inhibits Seizures in Models of Generalized Epilepsy Poster 02.209; Session P02: Epilepsy: Novel Therapeutics and Basic Science; Tuesday, March 19, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m. To schedule an interview with an investigator, please contact Elizabeth Likly at firstname.lastname@example.org.
Epilepsy is a medical condition that causes seizures affecting a variety of cognitive and physical functions. More than two million people in the U.S. are estimated to be affected by epilepsy with about 200,000 new cases of epilepsy diagnosed each year.1
Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company headquartered in Maple Grove, Minnesota that focuses on product growth and innovation for branded, branded-generic and generic pharmaceuticals. Upsher-Smith has a particular focus on providing therapies to assist people suffering from central nervous system diseases (including epilepsy, Parkinson's disease and Alzheimer's disease) and also markets products relating to cardiology, dermatology and women's health. In addition to products currently marketed, Upsher-Smith has an emerging neurology pipeline with three products in clinical development, two of which are in Phase III clinical trials. For more information, visit www.upsher-smith.com.
1. Epilepsy Foundation. About Epilepsy. Available at: http://www.epilepsyfoundation.org/aboutepilepsy/whatisepilepsy/statistics.cfm. Accessed February 4, 2013.
|SOURCE Upsher-Smith Laboratories, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
Related medicine technology :
1. Innophos CFO To Present At 2013 Sidoti Emerging Growth Conference
2. Frost & Sullivan Recognizes Cytomedix for its Pioneering System that Supports the Emerging Regenerative Therapies Market
3. Emerging Pharmaceutical Market in South Africa - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process
4. The 113th Canton Fair: "Great Opportunities for Emerging Markets"
5. Emerging Growth Pharmaceutical Company Creates Gravitational Pull Towards Their Products
6. Cumberland Emerging Technologies Expands Life Sciences Center
7. Innovative CA Tumor Marker Tests Technologies and Emerging Markets
8. Emerging Data on USL261 (Intranasal Midazolam) to Be Presented at the 66th Annual Meeting of the American Epilepsy Society
9. Innovative Hematology and Flow Cytometry Technologies and Emerging Markets
10. Henry Schein Announces Featured Speakers For The "Recovery Empowerment Symposium: Emerging From The Storm"
11. Cepheid Announces Executive Vice President Emerging Markets
(Date:4/19/2017)... DIEGO , April 19, 2017 Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento. The ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ... Breaking Medicine Technology:
(Date:4/21/2017)... West Palm Beach, FL (PRWEB) , ... April 21, 2017 , ... The staff at ... FACS , will be taking part in the 2017 London Marathon. Set to take place ... variety of charitable organizations. This year, Dr. Schwartz will run as part of team EMPOWER, ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Brady ... that its B-595 and B-7569 vinyl label materials received certification ... warning labels are tested to remain intact and legible, for use on chemical drums ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The Patient Advocacy ... Health System, with the 2017 Ruth Ravich Patient Advocacy Award in recognition ... advocates. DeVaro was honored with the award at The Beryl Institute’s annual Patient ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 to ... and preventing substance use disorders. , The mission of AWARE is to ...
(Date:4/21/2017)... ... 21, 2017 , ... Metrasens is honoured to have won ... most prestigious award for business success. The company has been recognized for ... grown by a total of 400% over the last six years. , Metrasens ... Breaking Medicine News(10 mins):